HIV Infections
Conditions
Keywords
microbicides, safety, effectiveness, Tenofovir gel, HIV, young women, HIV Seronegativity
Brief summary
This phase IIb, two-arm, double-blinded, randomised, placebo controlled trial comparing 1% Tenofovir gel with a placebo gel is an expanded safety and effectiveness trial involving 900 young women at risk of sexually transmitted HIV infection. Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study gel within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. All participants will receive HIV risk reduction counselling, condoms, and syndromic treatment of sexually transmitted infections, if required.
Detailed description
Purpose: To assess the safety and effectiveness of tenofovir gel, a candidate vaginal microbicide, in sexually active women at risk for human immunodeficiency virus (HIV) infection in South Africa. Design: Phase IIb, two-arm, double-blind, randomised, controlled trial comparing 1% tenofovir gel with a placebo gel. Study Population: Sexually active, HIV-uninfected women aged 18 to 40 years in South Africa Study Size: 900 women Treatment Regimen: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel or placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period. Study Duration: Approximately 30 months in total. Accrual will require approximately 14 months and follow-up will continue until 92 incident HIV infections are observed in the study, which is expected to occur approximately 16 months after the end of the accrual period. Primary Objective: To evaluate the effectiveness and safety of a candidate vaginal microbicide, tenofovir gel, when applied intravaginally by women, in preventing sexually transmitted HIV infection. Secondary Objectives: * To assess the impact, if any, of tenofovir gel on the incidence rate of deep epithelial disruption * To assess the impact, if any, of tenofovir gel on viral load in women who become infected with HIV during the trial. * To assess tenofovir resistance in HIV seroconvertors in the trial * To ascertain the impact, if any, of tenofovir gel on pregnancy rates and outcomes * To assess the impact, if any, of product hold at study exit on HIV infection and tenofovir resistance Ancillary Objective •To assess the impact, if any, of tenofovir gel in preventing sexually transmitted infections, including herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections. Study sites: * CAPRISA Vulindlela Clinical Research Site, KwaZulu-Natal, South Africa * CAPRISA eThekwini Clinical Research Site, Durban, South Africa
Interventions
DRUGTenofovir gel
Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
DRUGPlacebo (Universal HEC placebo)
Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Sponsors
FHI 360
United States Agency for International Development (USAID)
CONRAD
Centre for the AIDS Programme of Research in South Africa
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-40 years (inclusive) * Able and willing to provide written informed consent to be screened for, and to enrol in, the study. * Able and willing to provide adequate locator information for study retention purposes. * Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening. * HIV negative on testing performed by study staff within 30 days of enrolment. * Have a negative pregnancy test which was performed by study staff within 21 days of enrolment * Agree to use a non-barrier form of contraceptive * Agree to adhere to study visits and procedures
Exclusion criteria
* History of adverse reaction to latex. * Plans any of the following during the next 16 to 30 months (depending the anticipated date of study completion): * To travel away from the study site for more than 30 consecutive days. * To relocate away from the study site. * To become pregnant * To enrol in any other study of an investigational product or behaviour modification related to HIV prevention. * Has a creatinine clearance \<50ml/min, as estimated using the method of Cockcroft and Gault(33). * Has active Hepatitis B infection (since January 2009) * Has a clinically apparent pelvic examination finding (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met. * Has in the past year participated in any research related to any vaginally applied product/s. * Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has commenced. * Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in HIV status compared between arms (tenofovir vs placebo) | Baseline and monthly HIV testing for the duration of the study, an expected average of 18 months | The effectiveness of tenofovir against HIV infection will be measured by comparing the incidence of HIV in the tenofovir arm with that in the placebo arm |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the impact of tenofovir gel on viral load | measured at the first visit post HIV infection, and again 3 months later | To assess the impact, if any, of tenofovir gel on viral load in women who become infected with HIV during the trial. |
| To assess tenofovir resistance in HIV seroconvertors in the trial | performed at the post-seroconversion visit | — |
| Change in incidence rate of deep epithelial disruption compared between arms | Baseline and monthly assessments for the duration of the study, an expected average of 18 months | To assess the impact, if any, of tenofovir gel on the incidence rate of deep epithelial disruption |
| To assess the impact, if any, of product hold at study exit on HIV infection and tenofovir resistance | Assessed at post study visit | Assess new HIV seroconversions in the period between study exit and the post study visit (range 2 to 4 months) |
| Impact of tenofovir gel on other sexually transmitted infections | Change from baseline to study exit | To assess the impact, if any, of tenofovir gel in preventing sexually transmitted infections, including herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections |
| To ascertain the impact, if any, of tenofovir gel on pregnancy rates and outcomes | Assessed at baseline and monthly for the duration of the study, an expected average of 18 months | — |
Countries
South Africa
Outcome results
None listed